Related Experiment Video
Updated: Nov 15, 2025

08:47
Author Spotlight: In Vitro Co-Culture Model for Studying Microglia-Neuronal Interactions in Disease Conditions
Published on: July 26, 2024
3.0K
Targeting Microglia-Synapse Interactions in Alzheimer's Disease
Gaia Piccioni1,2, Dalila Mango1,3, Amira Saidi1,2
1Laboratory Pharmacology of Synaptic Plasticity, European Brain Research Institute, 00161 Rome, Italy.
International Journal of Molecular Sciences
|March 3, 2021
Summary
Microglia, immune cells in the brain, actively shape synaptic plasticity and cognition. Maintaining their healthy ramified state is crucial, as Alzheimer's disease disrupts this, leading to cognitive decline.
Area of Science:
- Neuroscience
- Immunology
- Cell Biology
Background:
- Microglia, traditionally viewed as resting immune cells, are increasingly recognized for their dynamic roles in the brain.
- These cells interact closely with neurons at synapses, influencing activity-dependent plasticity.
Purpose of the Study:
- To review the emerging roles of microglia in synaptic plasticity in both healthy and diseased states.
- To highlight the link between microglial function, synaptic health, and cognitive processes.
- To identify potential therapeutic targets for neurodegenerative diseases.
Main Methods:
- Literature review focusing on recent research in neuroimmunology and synaptic plasticity.
- Analysis of evidence linking microglial morphology and function to neuronal activity.
- Examination of molecular pathways involved in microglial regulation and their impact on neurodegeneration.
Main Results:
- Ramified microglia are dynamically involved in synaptic plasticity, modulating neuronal function through secreted factors.
- Microglia are essential for brain development and cognitive function.
- Alzheimer's disease pathology alters microglial morphology, contributing to synapse loss and cognitive impairment.
Conclusions:
- Maintaining the ramified state of microglia is vital for normal synaptic plasticity and cognition.
- Microglial TREM2 and CSF1R signaling pathways represent promising therapeutic targets for Alzheimer's disease and other neurodegenerative disorders.
Related Concept Videos
Alzheimer's Disease: Treatment
565
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
565
Alzheimer's Disease: Overview
1.1K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.1K

